Table 5.
Acute respiratory symptoms observed during the intervention period.
| Placebo(n = 47) | LF (n = 47) | p | |
|---|---|---|---|
| FEVER | |||
| Prevalence, n (%) | 30 (63.8) | 29 (61.7) | 1.000 |
| Fever days | 2 (0, 4) | 1 (0, 3) | 0.270 |
| Duration, days/episode | 2 (1.33, 3) | 1.67 (1, 2) | 0.216 |
| NASAL SECRETION/CONGESTION | |||
| Prevalence, n (%) | 47 (100) | 46 (97.9) | 1.000 |
| Nasal secretion/congestion days | 12 (4, 21) | 10 (4, 18) | 0.342 |
| Duration, days/episode | 4.25 (2, 6) | 4 (2.5, 5.75) | 0.942 |
| COUGH/SPUTUM | |||
| Prevalence, n (%) | 45 (95.7) | 38 (80.9) | 0.050 |
| Cough/sputum days | 9 (3, 15) | 5 (2, 13) | 0.243 |
| Duration, days/episode | 4 (2.1, 6) | 4 (2, 5.13) | 0.956 |
| FATIGUE | |||
| Prevalence, n (%) | 28 (59.6) | 27 (57.4) | 1.000 |
| Fatigue days | 2 (0, 6) | 1 (0, 3) | 0.197 |
| Duration, days/episode | 2.5 (1.54, 4) | 1.67 (1, 2) | 0.013 |
| OTHERS | |||
| Prevalence, n (%) | 4 (8.5) | 6 (12.8) | 0.740 |
| Others, days | 0 (0, 0) | 0 (0, 0) | 0.534 |
| Duration, days/episode | 1 (1, 2.5) | 1 (1, 1) | 0.610 |
Values represent the number (%) or the median (interquartile range).
Prevalence is defined as the number of participants who experienced more than one symptom.
Symptom days is defined as the cumulative number of symptomatic days.
Duration is defined as the mean of consecutive days per episode.
Otitis media and eye discharge associated with other respiratory symptoms.